Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$19.84 +6.3%	$18.88	$14.40 ▼ $47.00	$1.32B	1.39	909,959 shs	2.82 million shs
CPRX Catalyst Pharmaceuticals	$24.58 +0.2%	$23.59	$14.75 ▼ $26.16	$3.00B	0.7	1.10 million shs	933,233 shs
RVMD Revolution Medicines	$39.08 +3.6%	$37.53	$29.17 ▼ $62.40	$7.28B	1.11	1.51 million shs	1.81 million shs
SWTX SpringWorks Therapeutics	$46.68	$43.29	$28.21 ▼ $62.00	$3.52B	0.77	2.21 million shs	3.12 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	+6.32%	-2.60%	-5.21%	-3.55%	-42.02%
CPRX Catalyst Pharmaceuticals	+0.16%	+1.95%	+1.24%	+7.38%	+54.79%
RVMD Revolution Medicines	+3.58%	+0.72%	-3.91%	-4.07%	+3.63%
SWTX SpringWorks Therapeutics	0.00%	+0.89%	+0.95%	-19.18%	+14.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.9728 of 5 stars	4.5	0.0	0.0	3.4	0.0	0.0
CPRX Catalyst Pharmaceuticals	4.8786 of 5 stars	3.6	3.0	3.9	4.3	3.3	2.5
RVMD Revolution Medicines	4.2827 of 5 stars	4.5	0.0	4.7	3.6	2.5	0.0
SWTX SpringWorks Therapeutics	1.7781 of 5 stars	3.1	2.0	0.0	2.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$53.90	171.67% Upside
CPRX Catalyst Pharmaceuticals	3.13	Buy	$32.29	31.35% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	71.66% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	12.62% Upside

Current Analyst Ratings Breakdown

Latest RVMD, SWTX, CPRX, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/12/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$47.00 ➝ $47.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00
5/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.56M	174.24	N/A	N/A	$9.08 per share	2.19
CPRX Catalyst Pharmaceuticals	$534.65M	5.61	$2.29 per share	10.72	$3.30 per share	7.45
RVMD Revolution Medicines	$742K	9,810.45	N/A	N/A	$11.09 per share	3.52
SWTX SpringWorks Therapeutics	$219.67M	16.01	N/A	N/A	$10.01 per share	4.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	8/14/2025 (Estimated)
CPRX Catalyst Pharmaceuticals	$71.41M	$1.57	20.83	11.54	3.31	31.01%	40.79%	34.87%	8/6/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$325.10M	-$3.41	N/A	N/A	N/A	-134.73%	-46.74%	-41.12%	8/6/2025 (Estimated)

Latest RVMD, SWTX, CPRX, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
CPRX Catalyst Pharmaceuticals	N/A	5.11	4.92
RVMD Revolution Medicines	N/A	14.24	14.24
SWTX SpringWorks Therapeutics	N/A	6.16	6.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
CPRX Catalyst Pharmaceuticals	79.22%
RVMD Revolution Medicines	94.34%
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
CPRX Catalyst Pharmaceuticals	10.40%
RVMD Revolution Medicines	8.20%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
CPRX Catalyst Pharmaceuticals	80	121.98 million	106.15 million	Optionable
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	68.73 million	Optionable

RVMD, SWTX, CPRX, and CLDX Headlines

Recent News About These Companies

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 28 at 3:15 AM | marketbeat.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27 at 6:50 PM | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 27 at 12:05 AM | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

ProShare Advisors LLC Has $827,000 Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 26, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives $52.57 Average Price Target from Analysts

May 26, 2025 | americanbankingnews.com

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?

May 25, 2025 | marketbeat.com

Deutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 25, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from Analysts

May 25, 2025 | marketbeat.com

Palisades Investment Partners LLC Buys 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 24, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Bank of America Corp DE

May 24, 2025 | marketbeat.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025 | globenewswire.com

Woodline Partners LP Buys 108,512 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 22, 2025 | marketbeat.com

Zimmer Partners LP Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 22, 2025 | marketbeat.com

Velan Capital Investment Management LP Makes New $6.70 Million Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 21, 2025 | marketbeat.com

Rafferty Asset Management LLC Has $4.44 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 21, 2025 | marketbeat.com

30,811 Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Purchased by Tema Etfs LLC

May 20, 2025 | marketbeat.com

Ensign Peak Advisors Inc Lowers Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 19, 2025 | marketbeat.com

Sphera Funds Management LTD. Makes New $3.61 Million Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 18, 2025 | marketbeat.com

Patient Square Capital LP Invests $3.37 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD, SWTX, CPRX, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$19.84 +1.18 (+6.32%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$19.84 0.00 (-0.03%)

As of 05/29/2025 05:22 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Catalyst Pharmaceuticals NASDAQ:CPRX

$24.58 +0.04 (+0.16%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$24.47 -0.11 (-0.45%)

As of 05/29/2025 07:53 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Revolution Medicines NASDAQ:RVMD

$39.08 +1.35 (+3.58%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$39.52 +0.44 (+1.14%)

As of 05/29/2025 06:59 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

SpringWorks Therapeutics NASDAQ:SWTX

$46.68 0.00 (0.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$46.59 -0.09 (-0.19%)

As of 05/29/2025 05:32 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time